Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

Gallant ICD
Solutions

Single and Dual Chamber Implantable Cardioverter Defibrillators (ICD)

Technology
Join Our Email List

Technology Overview

Enhanced Detection and Treatment

Experience increased detection capabilities in traditionally challenging arrhythmias with Abbott’s new discriminator, VF Therapy Assurance.

Decrease time to treatment for arrhythmias in patients likely to be hemodynamically unstable


>800 patients annually with challenging arrhythmias could have their lives saved because of VF Therapy Assurance1

/content/dam/cv/cardiovascular/hcp/products/cardiac-rhythm-management/gallant-crt-d/graphics/crm-gallant-crtd-icon-clock-arrow-dotted-90x90.jpg

Safer Management of Care

Manage high DFTs with the industry’s most flexible option, DeFT Response™ technology. The programming options are designed to optimize rescue therapy to meet each patient’s unique physiology and changing needs.

 

Customized matching of shock waveform to patients’ cellular response time to lower DFTs

100% success in preserving a 10J safety margin with DeFT Response technology vs. 83% achievement of 10J safety margin in fixed-tilt group of patients with competitive devices2

Reduced Inappropriate Therapy

ShockGuard™ technology with DecisionTx™ programming is designed to reduce inappropriate therapy and minimize the need for programming adjustments at implant.

 

98.4% of patients did not receive inappropriate shocks at 1 year (CI: 97.2 -99.2, p<0.0001)3

Stay Informed

Sign up to hear about our technology, education opportunities, and more.

Join Our Email List

Read the Latest Blog Article

Stay up to date with recent news, product highlights, and case studies.

Visit the Abbott CRM Blog
Manuals & Technical Resources

Manuals & Technical Resources

Reimbursement & Coding

Reimbursement & Coding

Customer Service

Customer Service

References

  1. Data on file. 60101422 Internal Validation Report. Total 2019 global high-voltage implants, all manufacturers, estimated to be 440,434 units (Source: Abbott Market Research).
  2. Gabriels J, Budzikowski AS, Kassotis JT. Defibrillation waveform duration adjustment increases the proportion of acceptable defibrillation thresholds in patients implanted with single-coil defibrillation leads. Cardiology. 2013;124(2):71-75.
  3. Veltmann C, Wöhrle A, Busch M, et al. Reduction of inappropriate shocks of ICDs with enhanced SVT discriminators. EUROPACE presentation; 2017.

MAT-2007455 v4.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
abbott logo

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-1900882 v13.0